Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;16(2):73-74.
doi: 10.1038/s41571-018-0156-2.

Advances in patient care through increasingly individualized therapy

Courtney D DiNardo  1 , Alexander E Perl  2
Affiliations

Advances in patient care through increasingly individualized therapy

Courtney D DiNardo et al. Nat Rev Clin Oncol. 2019 Feb.

Abstract

Standfirst | In 2018, the acute myeloid leukaemia treatment landscape expanded notably, with the findings of several trials leading to the approval of novel targeted therapies. Furthermore, comprehensive sequencing of patient samples revealed the effects of co-occurring mutations and gene- expression patterns on drug sensitivity, providing hope that future treatment options will become increasingly precise and personalized.

PubMed Disclaimer

Conflict of interest statement

Competing interests

C.D.D. is a consultant of Abbvie, Agios, and Celgene and has received honoraria from Bayer, Jazz, Karyopharm, Medimmune, and Syros as an advisory board member. A.E.P. is a consultant for Abbvie, Arog, Astellas, and Daiichi Sankyo. Additionally he has received honoraria from Actinium Pharmaceuticals, Agios, Jazz Pharmaceuticals, NewLink Genetics, Novartis, and Takeda as an advisory board member.

Figures

Fig. 1 |
Fig. 1 |. Developments in the treatment of AML.
AML, acute myeloid leukaemia; CR, complete remission; CRc, composite complete remission; CRh, CR with incomplete haematological recovery; CRi, complete remission with incomplete neutrophil or platelet recovery; EFS, event-free survival; HMA, hypomethylating agent; ITD, internal tandem duplication; MDS, myelodysplastic syndrome; OS, overall survival; ORR, overall response rate; R/R, relapsed and/or refractory.
See this image and copyright information in PMC

References

    1. Noone AM HN, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975–2015. 2018.
    1. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. The New England journal of medicine. 2017;377(5):454–64. - PMC - PubMed
    1. Cortes J, Perl AE, Dohner H, Kantarjian H, Martinelli G, Kovacsovics T, et al. Quizar – ITD Cohort 2)tinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. The Lancet Oncology. 2018;19(7):889–903. - PMC - PubMed
    1. Cortes JKS, Martinelli G, Perl AE, Ganguly S, Russell N, Kramer A, Dombret H, Hogge D, Jonas BA, Leung AY, Mehta P, Montesinos P, Radsak M, Sica S, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ. QUIZARTINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-INTERNAL TANDEM DUPLICATION–MUTATED (MUT) RELAPSED/REFRACTORY AML IN THE PHASE 3, RANDOMIZED, CONTROLLED QUANTUM-R TRIAL. EHA 2018;LB2600.
    1. DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. The New England journal of medicine. 2018;378(25):2386–98. - PubMed

Publication types

Substances